Log in

NASDAQ:ETONEton Pharmaceuticals Stock Price, Forecast & News

$6.74
+0.06 (+0.90 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.70
Now: $6.74
$7.15
50-Day Range
$4.96
MA: $5.65
$6.68
52-Week Range
$2.50
Now: $6.74
$7.70
Volume632,161 shs
Average Volume196,944 shs
Market Capitalization$141.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETON
CUSIPN/A
CIKN/A
Phone847-787-7361

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.59 per share

Profitability

Net Income$-18,320,000.00

Miscellaneous

Employees15
Market Cap$141.00 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable
$6.74
+0.06 (+0.90 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

How has Eton Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ETON shares have increased by 60.5% and is now trading at $6.74.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Eton Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eton Pharmaceuticals
.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Eton Pharmaceuticals
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals Inc (NASDAQ:ETON) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.28. The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $1.62 million.
View Eton Pharmaceuticals' earnings history
.

What price target have analysts set for ETON?

3 brokerages have issued twelve-month price targets for Eton Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Eton Pharmaceuticals' stock price to reach $14.00 in the next year. This suggests a possible upside of 107.7% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals
.

Has Eton Pharmaceuticals been receiving favorable news coverage?

News articles about ETON stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Eton Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Eton Pharmaceuticals
.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 750,200 shares, an increase of 33.1% from the June 30th total of 563,500 shares. Based on an average trading volume of 129,700 shares, the days-to-cover ratio is currently 5.8 days. Currently, 5.3% of the shares of the company are sold short.
View Eton Pharmaceuticals' Current Options Chain
.

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64)

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Westside Investment Management Inc. (0.39%), First Trust Advisors LP (0.13%) and UBS Group AG (0.02%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman.
View institutional ownership trends for Eton Pharmaceuticals
.

Which institutional investors are selling Eton Pharmaceuticals stock?

ETON stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Eton Pharmaceuticals
.

Which institutional investors are buying Eton Pharmaceuticals stock?

ETON stock was bought by a variety of institutional investors in the last quarter, including Westside Investment Management Inc., and First Trust Advisors LP. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Sean Brynjelsen, and William Wilson Troutman.
View insider buying and selling activity for Eton Pharmaceuticals
.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $6.74.

How big of a company is Eton Pharmaceuticals?

Eton Pharmaceuticals has a market capitalization of $141.00 million and generates $460,000.00 in revenue each year. The company earns $-18,320,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.